Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

Summary

The aim of the study was to determine whether a short-term treatment with simvastatin or fenofibrate may result in beneficial anti-inflammatory and antithrombotic effects in patients with high risk of coronary artery disease. In a randomized, double-blind study, we compared markers of inflammation, thrombin formation and platelet activation in patients with LDL cholesterol >130 mg/dl assigned to receive simvastatin (40 mg/d; n=20) or micronised fenofibrate (160 mg/d; n=22) for 28 days. Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Interleukin-6, soluble CD40 ligand, and monocyte chemoattractant protein-1 levels decreased significantly (by 20 to 50%) in both treatment groups on days 3 and 28. Soluble cell adhesion molecules remained unchanged in both groups. Simvastatin and fenofibrate significantly lowered plasma concentrations of thrombin-antithrombin complexes on days and 28, but not platelet β-thromboglobulin (βTG) levels. Soluble P-selectin was lowered only in the simvastatin group. The total amount of thrombin generated at the site of microvascular injury also declined (by about 30%) as early as after 3 days of fenofibrate or simvastatin therapy, whereas βTG release was reduced only in the simvastatin group on days 3 and 28.All the effects were independent of the changes in lipid profiles. Our results suggest that statins and fibrates can exert antithrombotic and anti-inflammatory effects as early as after 3 days of therapy. However, in contrast to statins, fibrates have no influence on platelet function within one month of therapy.

Keywords

Statins - fibrates - cholesterol - coagulation - inflammation

• References

• 1 Undas A, Celinska-Lowenhoff M, Kaczor M. et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004; 91: 1065-77.
• 2 Szczeklik A, Musial J, Undas A. et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
• 3 Musial J, Undas A, Undas R. et al. Treatment with simvastatin and low dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline high cholesterol levels. Thromb Haemost 2001; 85: 221-5.
• 4 Puccetti L, Pasqui AL, Pastorelli M. et al. Time-dependent effect of statins on platelet function in hypercholesterolemia. Eur J Clin Invest 2002; 32: 901-8.
• 5 Wiesbauer F, Kaun C, Zorn G. et al. HMG-CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002; 135: 284-92.
• 6 Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3.
• 7 Musial J, Undas A, Gajewski P. et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001; 77: 247-53.
• 8 Plenge JK, Hernandez TL, Weil KM. et al. Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-52.
• 9 Marx N, Sukhova GK, Collins T. et al. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-31.
• 10 Gervois P, Kleemann R, Pilon A. et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferators-activated receptor-alpha activator fenofibrate. J Biol Chem 2004; 279: 16154-60.
• 11 Neve BP, Corseaux D, Chinetti G. et al. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001; 103: 207-12.
• 12 Bröijersen A, Hamsten A, Silveira A. et al. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost 1996; 76: 171-6.
• 13 National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-445.
• 14 Laufs U, Wassmann S, Hilgers S. et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88: 1306-7.
• 15 Tsunekawa T, Hayashi T, Kano H. et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-9.
• 16 Sebestjen M, Keber I, Zegura B. et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004; 92: 1129-35.
• 17 Melenovsky V, Malik J, Wichterle D. et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002; 144: E6.
• 18 Wang TD, Chen WJ, Lin JW. et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170: 315-23.
• 19 Staels B, Koenig W, Habib A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-3.
• 20 Kleemann R, Verschuren L, De Rooij BJ. et al. Evidence for antiinflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in cultured human hepatocytes in vitro. Blood 2004; 103: 4188-94.
• 21 Jialal I, Stein D, Balis D. et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
• 22 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-51.
• 23 Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-20.
• 24 Schonbeck U, Gerdes N, Varo N. et al. Oxidized low-density lipoprotein augments and 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 2888-93.
• 25 Andre P, Nannizzi-Alaimo L, Prasad SK. et al. Platelet- derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
• 26 Waehre T, Damas JK, Gullestad L. et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors do regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003; 41: 1460-7.
• 27 Pasceri V, Chang J, Willerson JT. et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-4.
• 28 Kowalski J, Okopien B, Madej A. et al. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther 2003; 41: 241-7.
• 29 Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolemia. Clin Sci 2004; 106: 215-17.
• 30 Meroni PL, Tremoli E. Modulation of adhesion molecule expression on endothelial cells: to be or not to be?. J Thromb Haemost 2003; 1: 2280-2.
• 31 Bruni F, Puccetti L, Pasqui AL. et al. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clin Exp Med 2003; 3: 45-53.
• 32 Puccetti L, Pasqui AL, Pastorelli M. et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90: 476-82.
• 33 Puccetti L, Sawamura T, Pasqui AL. et al. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 2005; 35: 47-51.
• 34 Huhle G, Abletshauser C, Mayer N. et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95: 229-34.
• 35 Koh KK, Ahn JY, Jin DK. et al. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 2004; 97: 239-44.
• 36 Laustiola K, Lassila R, Koskinen P. Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during physical stress. Clin Pharmacol Ther 1988; 43: 302-7.
• 37 Kyrle PA, Westwick J, Scully MF. et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man–effect of low-dose aspirin. Thromb Haemost 1987; 57: 62-6.
• 38 Blann AD, Lip GY, Beevers DG. et al. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
• 39 Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 2004; 109: II18-26.
• 40 Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?. Curr Opin Lipidol 2003; 14: 575-83.